PT Prodia Widyahusada Tbk · IDX:PRDA
PT Prodia Widyahusada Tbk — 9M2026 Earnings Presentation
20 slides from PT Prodia Widyahusada Tbk's earnings presentation, November 2026
Slide 1: 9M2026 Company Update
9M2026 Company Update PT Prodia Widyahusada Tbk | PRDA.JK
Slide 2: Disclaimer
This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By viewing all or
Slide 3: Company Overview
Company Overview
Slide 4: 9M2026 Key Highlights
9M2026 Key Highlights Key Player in Private Independent Clinical Lab chain since 1973 Start from 2025, Prodia expands networks through IDR 1.71 Trillion Current Initiatives strategic collaboration in SEA Market and optimization USD 95.1 Million of clinical services 2024 Jun 2025 Nov 2025 2026 9M2026
Slide 5: Continuous Improvement in a Challenging Market
Continuous Improvement in a Challenging Market Ensure sustainability business with innovation, growth, and optimization Visits Revenue (in Million) (in IDR Trillion) CAGR* CAGR >3.0 * 2.3 -1.8% 4.0% >2.7 1.9 Prodia has strengthen the fundamental and generated continuous 2020 2021 2022 2023 2024 2025
Slide 6: Business Highlights
e fs e Sustainability for e é o Cz ‘di a Business Highlights nett
Slide 7: The Comprehensive Center of Excellence
The Comprehensive Center of Excellence Delivering personalization and precision in multiple customer segments Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation One-stop shop, Multiomics General Medical Preventive Treatment offering th
Slide 8: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model Centralized core operations (hub) while efficiently distributing services through multiple outlets (spokes) 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved Centralized information with Prodia Clinical Labs, Hospitals
Slide 9: Maintain Strong and Long-Term Relationship
Maintain Strong and Long-Term Relationship Generate new tests and ongoing referrals in partnership with medical & scientific community Strong relationships through the work of Introduced new tests, such as HPV-DNA High Risk Self- more than 500 Marketing and Collection (My HPV Test), Maternal Cell Co
Slide 10: Be The Next Generation Laboratory
Be The Next Generation Laboratory To deliver precision medicine with comprehensive lab services Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Predictive & Separation Science Diagnostic Laboratory Laboratory Next Generation Laboratory Anatomical Pathology Cancer Molecular La
Slide 11: Business Updates
Business Updates
Slide 12: Expand Our Presence with Diverse Models
Expand Our Presence with Diverse Models With strategic expansion of outlets, ensuring proximity to our customers FY2025 9M2026 Digital Platform Optimization 2026 Outlet Development Target >3 Hospital Labs Management 402 395 Outlets Outlets includes hospital lab & genomic site U by Prodia > 20 POC Ou
Slide 13: Financial Updates
Financial Updates
Slide 14: Revenue Growth Strengthen in 9M2026
Revenue Growth Strengthen in 9M2026 Supported by broad-based growth across customer segments Revenue (Unaudited) Quarterly Revenue (Unaudited) In IDR Billion In IDR Billion 9M21-9M26 CAGR -3.0% 2021 2022 2023 2024 2025 2026 9M25-9M26 Growth: +8.3% Revenue continued to 1,991 grow in 9M2026, reaching
Slide 15: 9M2026 Financial Performance
9M2026 Financial Performance Improved operating cost efficiency supports profitability amid margin pressure Cost of Revenue (COR) Gross Profit OPEX Net Income in IDR Billion in IDR Billion In IDR Billion In IDR Billion 9M21-9M26 CAGR -0.4% 9M21-9M26 CAGR -4.7% 9M21-9M26 CAGR +6.3% 9M21-9M26 CAGR -24
Slide 16: 9M2026 Financial Summary
9M2026 Financial Summary Sustained growth with improving profitability (in IDR Bn) 9M2026 9M2025 Change (in IDR Bn) 9M2026 9M2025 Change Revenue 1,711.2 1,580.5 8.3% Total Asset 2,621.6 2,599.3 0.9% Gross Profit 968.3 876.6 +10.5% Total Equity 2,352.6 2,275.4 3.4% EBIT 143.7 111.1 +29.3% EBT 158.9 1
Slide 17: Professional Team & Shareholding Information
Professional Team & Shareholding Information
Slide 18: Experienced & Professional Management Team
Experienced & Professional Management Team With more than 20 years experience in delivering growth and innovation of Prodia Board of Commissioners Andi Wijaya Gunawan Prawiro Soeharto Endang Hoyaranda Dewi Muliaty Keri Lestari Dandan Lukas Setia Atmaja Co-Founder and Chairman Co-Founder and Commissi
Slide 19: Shareholders Composition
Shareholders Composition Public free float is 24.5% of total with market cap of IDR 2.46 Trillion* PT Prodia Utama Bio Majesty Pte. Ltd. Public Treasury Stock 57% 12% 24.5% 6.5% 30% Distributor for Contract Research Research, therapy and medical Organization banking of stem cell equipment PT Prodia
Slide 20: THANK YOU
THANK YOU For further Information: PT Prodia Widyahusada Tbk Prodia Tower, Jalan Kramat Raya No. 150 Jakarta 10430, Indonesia Email: [email protected]